Capital Asset Advisory Services’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Asset Advisory Services’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-57	Closed	-$7K	–	721
2021 Q3	$7K	Sell	57 -70	-55%	-$9.01K	﹤0.01%	624
2021 Q2	$17K	Hold	127	–	–	﹤0.01%	592
2021 Q1	$17K	Hold	127	–	–	﹤0.01%	567
2020 Q4	$18K	Buy	127 +11	+9%	+$1.41K	﹤0.01%	912
2020 Q3	$13K	Buy	116 +109	+1,557%	+$12.2K	﹤0.01%	456
2020 Q2	$1K	Buy	+7	New	+$689	﹤0.01%	571

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Capital Asset Advisory Services's XBI Position: Q4 2021 in Review

Capital Asset Advisory Services sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2021, closing a stake of 57 shares — an estimated $7K sold.

Capital Asset Advisory Services first reported a position in XBI in Q2 2020 and held it in 6 quarters. The position peaked at $18K in Q4 2020. 700 funds tracked by Wall St. Rank hold XBI as of Q4 2021.

Capital Asset Advisory Services reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2021 after selling out during the quarter.
Capital Asset Advisory Services sold 57 State Street SPDR S&P Biotech ETF shares in Q4 2021, an estimated $7K.
Capital Asset Advisory Services first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 6 quarters.
Capital Asset Advisory Services's State Street SPDR S&P Biotech ETF position peaked at $18K in Q4 2020.
700 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2021.

Based on Capital Asset Advisory Services's 13F filing for Q4 2021, filed 4 Feb 2022.